Details of the Drug Reposition

General Information of This Drug (ID: DM0CL4I)

Drug Name
MCS-110   DM0CL4I
Synonyms Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Triple negative breast cancer DISAMG6N 2C60-2C65 Phase 2 [1]
Bone metastases DISTJXPA 2D50 Phase 2 [2]
Tenosynovial giant cell tumour DISYGQZI 2F7B Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Advanced malignancy DISAB5B8 2A00-2F9Z Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01643850) MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS). U.S. National Institutes of Health.